Critical Comparison: Elutia (NASDAQ:ELUT) and Immix Biopharma (NASDAQ:IMMX)

Elutia (NASDAQ:ELUT) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Earnings and Valuation

This table compares Elutia and Immix Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29 million	3.57	$53.38 million	$0.86	1.19
Immix Biopharma	N/A	N/A	-$29.44 million	($0.92)	-9.01

Elutia has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elutia and Immix Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
Immix Biopharma	N/A	-73.24%	-59.20%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Elutia and Immix Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0	1	1	0	2.50
Immix Biopharma	1	1	4	0	2.50

Elutia currently has a consensus target price of $6.00, indicating a potential upside of 485.37%. Immix Biopharma has a consensus target price of $19.50, indicating a potential upside of 135.22%. Given Elutia’s higher probable upside, analysts clearly believe Elutia is more favorable than Immix Biopharma.

Institutional & Insider Ownership

74.0% of Elutia shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 27.6% of Elutia shares are held by insiders. Comparatively, 30.3% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Elutia has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500.

Summary

Elutia beats Immix Biopharma on 10 of the 12 factors compared between the two stocks.

About Elutia

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

About Immix Biopharma

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.